Form 4: Athira Pharma Director Barbara Kosacz Granted 20,900 Stock Options

Athira Pharma, Inc. Director Barbara Kosacz was granted 20,900 stock options with an exercise price of $0.3125, vesting based on time or the next annual meeting, as part of the company's outside director compensation policy.

Summary

• Athira Pharma, Inc. (ATHA) Director Barbara Kosacz acquired 20,900 stock options on May 30, 2025.
• The stock options have an exercise price of $0.3125 per share.
• Each option represents the right to buy one share of Athira Pharma Common Stock.
• The options will vest on the earlier of May 30, 2026, or the day immediately before the date of the next annual meeting of the Issuer's stockholders that occurs after May 30, 2025.
• The expiration date for these options is May 29, 2035.
• This grant was made pursuant to the terms of the Issuer's Outside Director Compensation Policy.

Sentiment

Score: 7

Explanation: The grant of stock options to a director is a standard compensation practice, aligning the director's interests with shareholder value creation. It is a routine transaction and not indicative of significant positive or negative news beyond standard corporate governance.

Positives

• The grant of stock options to a director aligns their financial interests with those of the shareholders, encouraging long-term value creation.
• This is a standard practice for compensating outside directors, indicating adherence to established corporate governance policies.

Future Outlook

The acquired stock options are subject to a vesting schedule, indicating that the director's full beneficial ownership of the underlying common stock is contingent on continued service until May 30, 2026, or the next annual meeting, aligning future incentives.

Management Comments

• The option reported was granted pursuant to the terms of the Issuer's Outside Director Compensation Policy.

Industry Context

The granting of stock options to directors is a common compensation practice across various industries, particularly in biotechnology and pharmaceuticals, to attract and retain experienced board members and align their long-term interests with company performance.

Comparison to Industry Standards

• Granting equity-based compensation, such as stock options, to outside directors is a standard practice in the biotechnology and pharmaceutical sectors, similar to companies like Biogen Inc. or Amgen Inc., which often use equity to incentivize long-term commitment and performance.
• The vesting schedule tied to either a specific date or the next annual meeting is a typical structure for director equity grants, ensuring continued engagement and oversight.

Corporate Governance

Related Party Transactions

• The grant of stock options to Barbara Kosacz, a director of Athira Pharma, Inc., constitutes a related party transaction as it involves compensation provided by the company to a member of its board of directors, executed under the company's established compensation policy.

Stakeholder Impact

• Shareholders: The grant aligns the director's interests with shareholder value, as the options' value increases with the company's stock price.
• Employees: No direct impact on employees is indicated by this specific filing.

Next Steps

• The stock options will vest on the earlier of May 30, 2026, or the day immediately before the date of the next annual meeting of the Issuer's stockholders that occurs after May 30, 2025.
• Upon vesting, the director will have the right to exercise the options and purchase 20,900 shares of common stock at the exercise price of $0.3125 per share, until the expiration date of May 29, 2035.

Key Dates

Recommendation

Keywords

Athira Pharma, ATHA, Form 4, SEC filing, stock options, director compensation, insider transaction, equity grant, beneficial ownership